# A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

> **NCT04145570** · PHASE4 · COMPLETED · sponsor: **Quadras Scientific Solutions** · enrollment: 24 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Erlotinib HCl 150 mg
- **DRUG:** Tarceva®

## Key facts

- **NCT ID:** NCT04145570
- **Lead sponsor:** Quadras Scientific Solutions
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-23
- **Primary completion:** 2008-11-09
- **Final completion:** 2008-11-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04145570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04145570, "A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04145570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*